Glucose tolerance after stem cell transplant study
Part of Hormones & metabolism clinical trials.
This study looks at blood sugar problems in people who received a stem cell transplant from a donor. It aims to understand how common these problems are and what might affect them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received a stem cell transplant from a donor between March 2019 and March 2024
- Your donor had a record of blood sugar or HbA1c tests
- You have a good physical fitness score (0-2 on the ECOG scale)
- You have survived at least 12 weeks after your transplant
- You are willing to sign a consent form and can follow the study rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at heart problems that can happen after a stem cell transplant from a donor (allogeneic). It aims to understand these risks better so doctors can help patients stay healthier after transplant.
This study tests if islet cells made from stem cells can be safely transplanted to help control blood sugar in people with diabetes. It may offer a new treatment option for those who need insulin.
This study tracks patients who have had or are planning to have a stem cell transplant. It helps doctors learn more about long-term outcomes and improve care for future patients.
This study looks at how your body processes medications after a stem cell transplant from a donor. It aims to find the best way to test your genes to improve future treatments.
This study looks at how the body processes sugar (glucose) in people with cirrhosis who are waiting for a liver transplant. It aims to track changes in blood sugar control before and after transplant, which may help improve care for patients with liver disease.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.